T7831

Nitecapone is a reversible inhibitor of S-COMT (IC50 values of 300 nM in rat liver)

Raxibacumab (ABthrax) is a humanized antibody targeting the protective antigen of Bacillus anthracis, with anti-infective activity, blocking the interaction of anthrax protective antigen with its receptor. It is used in studies of anthrax disease prevention.

Sontuzumab (AS1402) is a humanized monoclonal antibody targeting MUC1 that binds to the extracellular MUC1 peptide sequence PDTR (Kd≈1 nM) and can be used for breast cancer research.

Cifurtilimab (SEA-CD40) is a humanised monoclonal antibody acting as a CD40 agonist. It enhances binding to activated FcγRIIIa, exhibiting anticancer activity for treating pancreatic cancer, advanced solid tumours, and lymphoma.

Fazpilodemab (BFKB8488A) is a humanized agonistic bispecific antibody that targets fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. It is utilized in research pertaining to Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) [1].

Fianlimab (REGN3767) is a monoclonal antibody that targets human lymphocyte activation gene 3 (LAG-3) and exhibits antitumor activity. By blocking the immune checkpoint receptor LAG-3, fianlimab reverses T-cell exhaustion, thereby enhancing the antitumor immune response. Fianlimab is being investigated for use in the treatment of solid tumors such as melanoma.

Foravirumab (CR4098) is a monoclonal antibody targeting rabies virus glycoprotein (RABV-G) for the study of infectious diseases such as rabies.

Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. This compound effectively alleviates pain associated with feline osteoarthritis (OA).

Blinatumomab (AMG-10,MT-103) is a CD19/CD3 bispecific B-cell and T-cell binding antibody that directs T-cells to attack cancer cells by binding to both CD3 on T-cells and CD19 on cancer cells, and is used in acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.

Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS).